<DOC>
	<DOC>NCT00630435</DOC>
	<brief_summary>The purpose of this trial is to determine the equivalence of 3 new formulations of a Premarin速/medroxyprogesterone acetate (MPA) combination tablet to the currently marketed dosage form (Prempro速 [TM]). This study will be performed in healthy postmenopausal women. Each subject will participate in the study for approximately 14 weeks, including a screening evaluation within 3 weeks before the study, and four, 6-day, 5-night inpatient periods with at least a 21-day washout interval between each dose administration.</brief_summary>
	<brief_title>Study Comparing 3 New Formulations of Premarin速 0.625 mg/MPA 2.5 mg With a Reference Formulation</brief_title>
	<detailed_description />
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<criteria>Inclusion 1. Healthy postmenopausal women aged 35 to 70. 2. Body mass index of 18 to 35 kg/m2, weight must be at least 50 kg. 3. Nonsmoker or smoker of fewer than 10 cigarettes/day. Exclusion 1. History or presence of hypertension (&gt;139 mm Hg systolic or &gt;89 mm Hg diastolic). Can take up to 2 antihypertensive medications to keep blood pressure under control. 2. History within 1 year of study day 1 of alcohol or drug abuse. 3. Use of any investigational drug within 30 days before study day 1.</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Premarin速</keyword>
</DOC>